Close this search box.

Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy

The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.

Primary Sponsor

The University of Sydney

Collaborating Groups

Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)

Closing Date of Accrual

30 June 2019

Trial Chairperson

A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial Contact

Related Post

October 18, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

September 6, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing